Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells

By sjmartinez • March 13, 2023

Li S, Wang CS, Montel-Hagen A, Chen HC, Lopez S, Zhou O, Dai K, Tsai S, Satyadi W, Botero C, Wong C, Casero D, Crooks GM, Seet CS. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell Rep. 2023 Mar 10;42(3):112241. doi: 10.1016/j.celrep.2023.112241. Epub ahead of print. PMID: 36906850.

Tags: adoptive cell therapy, cancer immunotherapy, chimeric antigen receptor, CP, Hematology/Oncology, Immunology, innate lymphoid cells, pluripotent stem cells, Publications, Stem cell research, T cell development

Related Posts

Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial

Soto-Perez-de-Celis E, Dale W, Katheria V, Kim H, Fakih M, Chung VM, Lim D, Mortimer J, Cabrera Chien L, Charles K, Roberts E, Vazquez J,[...]

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher[...]

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan[...]